Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H22N6O3 |
Molecular Weight | 418.4485 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CCN(C1)C(=O)C=C)N2N=C(C#CC3=CC(OC)=CC(OC)=C3)C4=C(N)N=CN=C24
InChI
InChIKey=KEIPNCCJPRMIAX-HNNXBMFYSA-N
InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1
Molecular Formula | C22H22N6O3 |
Molecular Weight | 418.4485 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3650 Sources: https://www.ncbi.nlm.nih.gov/pubmed/30600916 |
3.9 nM [IC50] | ||
Target ID: CHEMBL4142 Sources: https://www.ncbi.nlm.nih.gov/pubmed/30600916 |
1.3 nM [IC50] | ||
Target ID: CHEMBL2742 Sources: https://www.ncbi.nlm.nih.gov/pubmed/30600916 |
1.6 nM [IC50] | ||
Target ID: CHEMBL3973 Sources: https://www.ncbi.nlm.nih.gov/pubmed/30600916 |
8.3 nM [IC50] |
PubMed
Title | Date | PubMed |
---|---|---|
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. | 2019 Aug |
|
Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer. | 2019 Dec |
|
TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure. | 2019 Feb 19 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:08:45 GMT 2023
by
admin
on
Sat Dec 16 09:08:45 GMT 2023
|
Record UNII |
4B93MGE4AL
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/19/2146
Created by
admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
|
||
|
FDA ORPHAN DRUG |
635018
Created by
admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1814961-20-0
Created by
admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
|
NO STRUCTURE GIVEN | |||
|
4B93MGE4AL
Created by
admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
|
PRIMARY | |||
|
100000180711
Created by
admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
|
PRIMARY | |||
|
4B93MGE4AL
Created by
admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
|
PRIMARY | |||
|
GH-182
Created by
admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
|
PRIMARY | |||
|
10879
Created by
admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
|
PRIMARY | |||
|
C114283
Created by
admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
|
PRIMARY | |||
|
DB15149
Created by
admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
|
PRIMARY | |||
|
1448169-71-8
Created by
admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
|
PRIMARY | |||
|
71621331
Created by
admin on Sat Dec 16 09:08:45 GMT 2023 , Edited by admin on Sat Dec 16 09:08:45 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|